Compounds as GLP-1r agonist

Abstract

The invention relates to a compound as a GLP-1R agonist and application of the compound in preparation of a medicine for treating and / or preventing GLP-1 receptor mediated diseases.

Description

Abstract The present invention relates to compounds as GLP‑1R agonist and their use in the preparation of drugs for the treatment and / or prevention of GLP‑1 receptor-mediated diseases.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof. in Y1 and Y2 are each independently selected from bonds, CR, CHR, and C(R)2; Y3 is selected from CR and C(R)2; X1 is selected from C, CH, and N; X2 is selected from CR, C(R)2, N, NR, O, and S; X3 and X7 are each independently selected from C, CH, and N; X4, X5, and X6 are each independently selected from CR, C(R)2, N, and NH; L1 is selected from L2 is C 1-6 Alkylene, the C 1-6 The alkylene group is optionally substituted with 1 to 6 substituents selected from the group consisting of: deuterium, halogen, =O, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkyl groups and deuterated C 3-6 cycloalkyl; Or, two carbon atoms on the same atom 1-6 Alkyl formation C 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -CH2O(C 3-6 cycloalkyl), C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl and deuterated C 1-6 Alkoxy; R is independently selected from H, deuterium, halogen, -OH, -CN, oxo (=O), C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 1 to 6 substituents selected from the group consisting of deuterium and halogens; R1 is selected from H, deuterium, halogens, -OH, -CN, -NR7R8, -NO2, -C(=O)R7, -C(=O)OR7, -OC(=O)R7, -C(=O)NR7R8, -C(=NH)NR7R8, -OC(=O)NR7R8, -NR9C(=O)NR7R8, -NR9C(=NH)NR7R8, -NR9C(=O)OR7, -NR7C(=O)R8, -SO2R7, -S(=O)(=NR7)R8, -N=S(=O)R7R8, -NR7SO2R8, -SO2NR7R8, -S(=O)(=NR7)NR8R9, -NR7SO2NR8R9, -P(=O)R7R8, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, or S, 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, or S, C 2-6 alkenyl and C 2-6 alkynyl group, in which, The C mentioned 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic, 5-6 membered heteroaryl, C 2-6 alkenyl, C 2-6 The alkynyl group may optionally be substituted by 1 to 6 substituents selected from the group consisting of: deuterium, halogen, oxo (=O), -OH, -NH2, -CN, -COOH, -C(=O)OC. 1-3 Alkyl group, -C(=O)OC 3-6 Cycloalkyl, -C(=O)NH-C 1-3 Alkyl group, -C(=O)NH-C 3-6 Cycloalkyl, -C(=O)N-(C 1-3 Alkyl)2、-SO2C 1-3 Alkyl, -SO2C 3-6 cycloalkyl, C 1-3 Alkyl, Halogenated C 1-3 Alkyl, deuterated C 1-3 alkyl; R2 is selected from C 3-12 Cycloalkyl groups, containing 1-4 3-12 membered heterocyclic groups selected from N, O, or S heteroatoms, C 6-12 Aryl groups and 5-12 heteroaryl groups containing 1-4 heteroatoms selected from N, O, or S, wherein C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl and 5-12 heteroaryl groups are optionally surrounded by 1-6 R groups. 21 replace; R 21 Selected from H, deuterium, halogens, -OH, -CN, oxo (=O), -NR7R8, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 1 to 6 substituents selected from the group consisting of: deuterium, halogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylamino, halogenated C 1-6 Alkylamino, C 3-6 cycloalkyl, halogenated C 3-6 Cycloalkyl, 3-6 membered heterocyclic alkyl containing 1-4 heteroatoms selected from N, O or S, and halogenated 3-6 membered heterocyclic alkyl containing 1-4 heteroatoms selected from N, O or S; R3 is selected from C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, C 6-12 Aryl groups and 5-12 heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl and 5-12 heteroaryl groups are optionally surrounded by 1-6 R groups. 31 Replace; or R3 is selected from C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, C 6-14 Aryl groups and 5-14 heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups are optionally surrounded by 1-6 R groups. 31 replace; R 31 Selected from H, deuterium, halogens, -OH, -CN, -NO2, oxo (=O), -NR7R8, =NR7, -C(=O)R7, -C(=O)OR7, -OC(=O)R7, -C(=O)NR7R8, -C(=O)NR9(NR7R8), -NR7C(=O)R8, -SO2R7, -S(=O)(=NR7)R8, -NR7SO2R8, -SO2NR7R8, -S(=O)(=NR7)NR8R9, -NR7SO2NR8R9, -P(=O)R7R8, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 6-12 aryl, comprising 1-4 5-12 membered heteroaryl groups selected from N, O and S heteroatoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 6-12 The aryl group and the 5-12 heteroaryl group are optionally substituted by 1-6 substituents selected from the following group: deuterium, halogen, -OH, -CN, -NO2, oxo(=O), -NR7R8, =NR7, -C(=O)R7, -C(=O)OR7, -OC(=O)R7, -C(=O)NR7R8, -NR7C(=O)R8, -SO2R7, -S(=O)(=NR7)R8, -NR7SO2R8, -SO2NR7R8, -S(=O)(=NR7)NR8R9, -NR7SO2NR8R9, -P(=O)R7R8, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 alkenyl, halogenated C 2-6 alkenyl, C 2-6 alkynyl group, C 3-6 cycloalkyl, halogenated C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, halogenated 4-6 membered heterocyclic groups, phenyl groups, halophenyl groups, 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, or S, haloated 5-6 membered heteroaryl groups, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, deuterated C 3-6 Cycloalkyl, deuterated 4-6-membered heterocyclic groups, deuterated phenyl, and deuterated 5-6-membered heteroaryl groups; Or, two Rs 31 Together with the atoms attached to it, they form C 5-10 Cycloalkyl, 4-10 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, phenyl, or 5-10 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 5-10 Cycloalkyl, 4-10-membered heterocyclic, phenyl, and 5-10-membered heteroaryl groups are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -OH, -CN, -NO2, oxo(=O), -NR7R8, =NR7, -C(=O)R7, -C(=O)OR7, -OC(=O)R7, -C(=O)NR7R8, -NR7C(=O)R8, -SO2R7, -S(=O)(=NR7)R8, -NR7SO2R8, -SO2NR7R8, -S(=O)(=NR7)NR8R9, -NR7SO2NR8R9, -P(=O)R7R8, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, phenyl, 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-6 Cycloalkyl, 4-6-membered heterocyclic, phenyl, and 5-6-membered heteroaryl groups are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -OH, -NH2, -CN, oxo (=O), C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, and halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylamino, halogenated C 3-6 Cycloalkyl groups, halogenated 4-6-membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, and deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkylamino, deuterated C 3-6 Cycloalkyl groups, containing 1-4 deuterated 4-6 membered heterocyclic groups selected from N, O and S heteroatoms; R4 is selected from H, deuterium, halogens, -CN, oxo (=O), and C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl and deuterated C 1-6 Alkoxy; Alternatively, two R4 atoms attached to the same carbon atom can form an exocyclic double bond (=CR). 41 R 42 C 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl and deuterated C 1-6 Alkoxy; Alternatively, R4 and R1 together with the atoms they are attached to form C. 5-10 Cycloalkyl, 5-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O and S, phenyl, or 5-10 membered heteroaryl group containing 1-4 heteroatoms selected from N, O and S, wherein the C 5-10 Cycloalkyl, 5-10-membered heterocyclic, phenyl, and 5-10-membered heteroaryl groups are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -OH, -CN, -NO2, oxo (=O), -NR7R8, =NR7, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl or deuterated C 1-6 Alkoxy; R 41 R 42 Each is independently selected from H, deuterium, halogen, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl and deuterated C 1-6 alkyl; R5 is selected from R 51 R 52 Each is independently selected from H, deuterium, halogen, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl and deuterated C 1-6 alkyl; R6 is selected from -LC 1-6 Alkyl, -LC 2-6 alkenyl, -LC 2-6 alkynyl, -LC 3-12 Cycloalkyl, -L-containing 1-4 3-12 membered heterocyclic groups selected from N, O and S heteroatoms, -LC 6-12 aryl and -L-containing 1-4 5-12-membered heteroaryl groups selected from N, O and S heteroatoms, wherein the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl and 5-12 heteroaryl groups are optionally surrounded by 1-6 R groups. 61 replace; R 61 Selected from H, deuterium, halogens, -OH, =O, -CN, -NR 6a R 6b C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 2-6 alkenyl, C 2-6 Alkyne, phenyl, or 5-10 heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 Alkyne, phenyl, or 5-10 heteroaryl groups are optionally surrounded by 1-6 R groups. 6e replace; Or, two Rs 61 Together with the atoms attached to it, they form an external double bond (=CR). 6c R 6d C 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl and deuterated C 1-6 Alkoxy; L is the key or can be chosen from -NR L -、-O-、-S-、C 1-6 Alkylene, -NR L -C 1-6 alkylene-, -C 1-6 Alkylene-NR L -、-OC 1-6 alkylene-, -C 1-6 alkylene-O-, wherein the C 1-6 The alkylene group is optionally substituted with 1 to 6 substituents selected from the group consisting of: deuterium, halogen, =O, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, deuterated C 3-6 Cycloalkyl, or two carbon atoms on the same atom 1-6 Alkyl groups can form C groups optionally substituted with 1-6 halogens. 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms; R 6a R 6b Each is independently selected from H and C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, containing 1-4 4-6 membered heterocyclic groups selected from N, O, and S heteroatoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkyl groups and deuterated C 3-6 cycloalkyl; R 6c R 6d Each is independently selected from the following groups: H, deuterium, halogens, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl and deuterated C 1-6 alkyl; R 6e Selected from deuterium, halogens, =O, -CN, -OH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, containing 1-4 4-6 membered heterocyclic groups selected from N, O, and S heteroatoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkyl groups and deuterated C 3-6 cycloalkyl; R L Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, phenyl, 5-10 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-6-membered heterocyclic, phenyl, 5-10-membered heteroaryl groups are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkyl groups and deuterated C 3-6 cycloalkyl; R7, R8, and R9 are each independently selected from H, -CN, -OH, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 6-12 aryl, comprising 1-4 5-12 membered heteroaryl groups selected from N, O and S heteroatoms, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 6-12 The aryl group and the 5-12 heteroaryl group are optionally substituted by 1-6 substituents selected from the following group: deuterium, halogen, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 Cycloalkyl groups, 4-6 membered heterocycles containing 1-4 heteroatoms selected from N, O, and S, halogenated 4-6 membered heterocycles containing 1-4 heteroatoms selected from N, O, and S, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, deuterated C 3-6 Cycloalkyl groups, containing 1-4 deuterated 4-6 membered heterocycles selected from N, O and S heteroatoms; Alternatively, R7, R8, or R8, R9 attached to the same nitrogen atom can form a 4-6 membered heterocyclic group containing 1-4 heteroatoms selected from N, O, and S, wherein the 4-6 membered heterocyclic group is optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -CN, -OH, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 Cycloalkyl groups, 4-6 membered heterocycles containing 1-4 heteroatoms selected from N, O, and S, halogenated 4-6 membered heterocycles containing 1-4 heteroatoms selected from N, O, and S, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, deuterated C 3-6 Cycloalkyl groups, containing 1-4 deuterated 4-6 membered heterocycles selected from N, O and S heteroatoms; n is 0, 1, 2, 3, 4, 5, or 6; It can be a single bond or a double bond.

2. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound has a structure selected from the following formula: in: X1, X2, X3, X4, X5, X6, X7, R, R1, R2, R3, R4, R5, R6, Y1, Y2, L1, L2, n as defined in claim 1.

3. The compound of claim 2, or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug, wherein the compound has a structure selected from the following formula: in: X1, X2, X3, X4, X5, X6, X7, R, R1, R2, R3, R4, R5, R6, L1, L2, n are as defined in claim 1.

4. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein... It has a structure selected from the following: in R is independently selected from H, deuterium, halogen, -OH, -CN, oxo (=O), C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O or S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 0-6 substituents selected from the group consisting of deuterium and halogens; m can be 0, 1, 2, 3, 4, 5, or 6.

5. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound has a structure selected from the group consisting of: in X1, X2, X3, X4, X5, X6, X7, R1, R2, R3, R5, R6, L2 as defined in claim 1; R4 groups are independently selected from H, deuterium, halogens, -CN, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 0-6 substituents selected from the group consisting of: deuterium, halogen, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy and halogenated C 1-6 Alkoxy; Alternatively, two R4 atoms attached to the same carbon atom can form an exocyclic double bond (=CR). 41 R 42 C 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 0-6 substituents selected from the group consisting of: deuterium, halogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy and halogenated C 1-6 Alkoxy; R 41 R 42 Each element is independently selected from the following groups: H, deuterium, halogens, and C. 1-6 Alkyl and halogenated C 1-6 alkyl; n can be 0, 1, 2, 3, 4, 5, or 6.

6. The compound of claim 1, or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug, wherein the compound has the following structure: R L21 Each is independently selected from: H, deuterium, methyl, ethyl, propyl, -CH2-O-cyclopropyl or -CH2CH2-O-cyclopropyl; X1 and X7 are each independently selected from CH and N; R1, R2, and R3 are as defined in claim 1.

7. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound has the following structure: X1 and X7 are each independently selected from CH and N; R1, R2, and R3 are as defined in claim 1.

8. The compound as described in any one of claims 1-7, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof. R1 represents H, deuterium, -CN, -NO2, and C. 1-3 Alkyl groups, halogens, -NR7R8, -NR7C(=O)R8, -NR9C(=O)NR7R8, -NR9C(=O)OR7, -NR9C(=NH)NR7R8, -OC(=O)NR7R8, -C(=O)R7, -C(=O)OR7, -OC(=O)R7, -C(=O)NR7R8, -SO2R7, -SO2NR7R8, -S(=O)(=NR7)NR8R9, -NR7SO2NR8R9, -P(=O)R7R8, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, or S, and 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, or S; the C 1-3 Alkyl, 4-6 membered heterocyclic, and 5-6 membered heteroaryl groups are optionally substituted by 1 to 6 substituents selected from the group consisting of: deuterium, halogen, -OH, -NH2, -CN, C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, deuterated C 1-3 alkyl; Preferably, R1 is selected from -CN, -CF3, -C(O)NR7R8, -P(O)R7R8, -C(=O)R7, -SO2NR7R8, 5-membered heterocyclic groups containing 1, 2, 3 or 4 heteroatoms selected from N, O or S, and 5-6-membered heteroaryl groups containing 1, 2, 3 or 4 heteroatoms selected from N, O or S. More preferably: R1 is selected from CN, -CF3, -CONH2, -CONHCH3, -CON(CH3)2, -COCH3, -P(=O)(CH3)2, -SO2NH2 or any of the following groups: in, R 111 R 112 Each is independently selected from H, deuterium, or C. 1-3 alkyl; R7 and R8 are each independently selected from H and C. 1-3 Alkyl, C 3-6 cycloalkyl, C 3-6 Heterocyclic group, C 5-6 Aryl or halogenated C 1-3 alkyl.

9. The compound according to any one of claims 1-7, or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug. R2 is a phenyl group, C 4-8 Cycloalkyl, 5-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, or S, or 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, or S; wherein the phenyl, 4-8 membered cycloalkyl, 5-6 membered heterocyclic, or 5-6 membered heteroaryl group is optionally surrounded by 1-6 R... 21 Replace; R 21 Selected from H, deuterium, halogens, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 cycloalkyl, halogenated C 1-3 Alkyl, C 3-6 cycloalkyl or halogenated C 3-6 cycloalkyl; Preferably, R2 is R 211 R 212 and R 213 Each is independently selected from H, deuterium, halogen, and C. 1-3 Alkyl, cyclopropyl, halogenated C 1-3 Alkyl or halocyclopropyl; more preferably, R 212 For F or -CF3, R 211 and R 213 Each is independently selected from H, deuterium, or C. 1-3 alkyl.

10. The compound according to any one of claims 1-7, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein R3 is selected from any one of the following groups: in, Indicates a single bond or a double bond; W1, W2, W3, W4, W5, W6, Z1, Z2, Z3, Z4, Z5, Z6, Z7, K1, K2, K3, K4, and V are each independently selected from -CR 31 -CR 31 R 31 -NR 31 -N-, O or S; R 31 As defined in claim 1.

11. The compound according to any one of claims 1-7, or its pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug, wherein R3 is selected from any one of the following groups: u0 is 0, 1, 2, 3, 4, or 5; u1 is 0, 1, 2, 3, or 4; u2 is 0, 1, 2, or 3; u3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8; u4 is 0, 1, 2, 3, 4, 5, or 6; u5 is 0, 1, 2, 3, 4, 5, or 6; u6 is 0, 1, 2, 3, 4, 5, or 6; u7 is 0, 1, 2, 3, 4, 5, 6, 7, or 8; u8 is 0, 1, 2, 3, or 4; u9 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11; u10 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; u11 is 0, 1, 2, 3... 4, 5, or 6; u12 is 0, 1, 2, 3, or 4; u13 is 0, 1, 2, 3, or 4; u14 is 0, 1, 2, 3, 4, 5, or 6; u15 is 0, 1, 2, 3, 4, 5, 6, 7, or 8; u16 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; u17 is 0, 1, 2, 3, 4, 5, 6, 7, or 8; u18 is 0, 1, 2, 3, 4, 5, or 6; u19 is 0, 1, 2, or 3; u20 is 0, 1, or 2; u21 is 0, 1, 2, 3, or 4; u22 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13; R 31 As defined in claim 1.

12. The compound of claim 11, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, R 31 Selected from: H, deuterium, halogen, -OH, -CN, oxo (=O), -NR7R8, -C(O)R7, -C(O)OR7, -OC(O)R7, -C(O)NR7R8, -NR7C(O)R8, -SO2R7, -S(O)(NR7)R8, -NR7SO2R8, -SO2NR7R8, -S(O)(NR7)NR8R9, -NR7SO2NR8R9, -P(O)R7R8, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O, and S, phenyl, 5-6 membered heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6-membered heterocyclic, phenyl, and 5-6-membered heteroaryl groups are optionally substituted by 1-6 substituents selected from the group consisting of: deuterium, halogen, -OH, -CN, -NR7R8, C. 1-3 Alkyl or C 1-3 Alkoxy; R7, R8, and R9 are each independently selected from H and C. 1-6 Alkyl, C 3-6 cycloalkyl; the C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted with 1 to 6 substituents selected from the group consisting of: deuterium, halogen, -CN, -OH.

13. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound has a structure selected from the group consisting of: in X1, X2, X3, X4, X5, X6, X7, R2, R3, R5, R6, L2 as defined in claim 1; Ring A is selected from the following group: C 5-10 Cycloalkyl, 5-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O and S, phenyl, 5-10 membered heteroaryl group containing 1-4 heteroatoms selected from N, O and S, wherein the C 5-10 Cycloalkyl, 5-10-membered heterocyclic, phenyl, and 5-10-membered heteroaryl groups are optionally substituted by 0-6 substituents selected from the group consisting of: deuterium, halogen, -OH, -CN, -NO2, oxo (=O), -NR7R8, =NR7, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy and halogenated C 1-6 Alkyl group. R4 is selected from the following groups: H, deuterium, halogens, -CN, C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl groups, 4-6 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, C 2-6 alkenyl, C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-6 membered heterocyclic groups, C 2-6 alkenyl, C 2-6 The alkynyl group is optionally substituted by 0-6 substituents selected from the group consisting of: deuterium, halogen, C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl group.

14. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound has a structure selected from the group consisting of: in: X1, X2, X3, X4, X5, X6, X7, R1, R2, R3, R4, R5, R6 as defined in claim 1; R L2 Each is independently selected from deuterium, halogens, =O, -CN, -OH, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkyl groups and deuterated C 3-6 cycloalkyl; Or, two R atoms on the same atom L2 Formation C 3-6 Cycloalkyl or containing 1-4 4-6 membered heterocyclic groups selected from N, O and S heteroatoms, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally substituted by 0-6 substituents selected from the group consisting of: deuterium, halogen, -CH2O(C 3-6 cycloalkyl), C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl and deuterated C 1-6 Alkyl group.

15. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein... Y1 and Y2 are each selected independently from the key; Optionally, Y3 is selected from -C(O)-; Optionally, X1 is selected from C, CH, and N; Optionally, X2 is selected from CR and C(R)2; Optionally, X3 is selected from C and CH; Optionally, X7 is selected from C, CH, and N; Optionally, X4, X5, and X6 are each independently selected from N and C. 1-6 Alkyl groups, CR, and C(R)2; Optionally, L1 is selected from Optionally, L2 is selected from -CH2-, -CH2-CH2-, Optionally, R is selected from H and C. 1-6 alkyl; Optionally, R1 is selected from H, deuterium, halogens, Optionally, R2 is selected from Optional, R 21 Selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl groups and C 3-6 cycloalkyl; Optionally, R3 is selected from 3-14 membered heterocyclic groups, C 6-14 Aryl groups and 5-14 heteroaryl groups containing 1-4 heteroatoms selected from N, O, and S; preferably, R3 is selected from... Optionally, R4 is selected from oxo (=O) and C. 1-6 alkyl; Optionally, R4 and R1 together with the atoms they are attached to form C 5-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 heteroatoms selected from N, O and S, or phenyl; Optionally, R5 is selected from Optionally, R6 is selected from -LC 2-6 alkynyl, -LC 3-12 Cycloalkyl, -L-containing 1-4 3-12 membered heterocyclic groups selected from N, O and S heteroatoms, -LC 6-12 The aryl group and -L-containing 1-4 5-12-membered heteroaryl groups selected from N, O, and S heteroatoms; preferably, R6 is selected from... Optional, R 61 Selected from C 1-6 Alkyl and Halogenated C 1-6 alkyl; Optionally, L is the key.

16. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite, or prodrug thereof, wherein the compound is selected from the group consisting of:

17. A pharmaceutical composition comprising any one of the compounds of claims 1-16 or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite or prodrug, and a pharmaceutically acceptable carrier or excipient.

18. Use of any compound of claims 1-16 or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite or prodrug, or pharmaceutical composition of claim 17 in the preparation of a medicament for treating and / or preventing GLP-1 receptor-mediated diseases.

19. Use of any compound of claims 1-16 or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite or prodrug, or the pharmaceutical composition of claim 17 in the preparation of a medicament for modulating GLP-1 receptors.

20. Use of any compound of claims 1-16 or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotopic compound, deuterated product, metabolite or prodrug, or the pharmaceutical composition of claim 17 in the preparation of a GLP-1R agonist.

21. The use as described in claim 18, wherein the disease is non-insulin-dependent diabetes mellitus, obesity, hypertension, hyperlipidemia, arteriosclerosis, hyperglycemia, impaired glucose tolerance, insulin-dependent diabetes mellitus, diabetic complications, coronary heart disease, cerebral infarction, non-alcoholic steatohepatitis, Parkinson's disease, or dementia.